12月10日,平台型Biotech公司百奥赛图正式登陆科创板,成为行业内为数不多的“先H后A”上市生物技术公司。相较于港股对未盈利生物科技企业上市的灵活,科创板在技术先进度和市场认可度等方面对硬科技企业提出更高的要求。作为2025年两地资本市场双向互动的又一标志性事件,百奥赛图“H+A”双资本平台的成功搭建,既接续了创新生物医药公司的上市热潮,也为具备核心创新能力的硬科技企业计划在科创板上市提振了...
Source Link12月10日,平台型Biotech公司百奥赛图正式登陆科创板,成为行业内为数不多的“先H后A”上市生物技术公司。相较于港股对未盈利生物科技企业上市的灵活,科创板在技术先进度和市场认可度等方面对硬科技企业提出更高的要求。作为2025年两地资本市场双向互动的又一标志性事件,百奥赛图“H+A”双资本平台的成功搭建,既接续了创新生物医药公司的上市热潮,也为具备核心创新能力的硬科技企业计划在科创板上市提振了...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.